Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Completed · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

This study is intended to assess the effect on HbA1c of different dose regimens of LX4211 in combination with metformin in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin monotherapy.

Key facts

Study ID

NCT01376557

Run by

Lexicon Pharmaceuticals

People needed

299

Starts

2011-06-01

Expected to finish

2012-05-01

Last updated by the study team

2014-10-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult subjects between the ages of 18 to 75 years, inclusive
• Confirmed diagnosis of Type 2 diabetes mellitus
• Meet required laboratory values at screening, including fasting plasma glucose less than 270 mg/dL
• Stable dose of metformin monotherapy greater than 1500 mg/day for at least 8 weeks
• Willing and able to provide written informed consent
• Willing and able to maintain consistent dietary, physical activity, and sleeping patterns throughout the study

You may not qualify if…

• History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes
• History of renal disease or clinically significant abnormal kidney function tests
• Presence of active hepatic disease or clinically significant abnormal liver function tests
• Subjects with a history of heart attack, severe/unstable angina, or coronary revascularization procedure within 6 months prior to study Day 1
• History of clinically significant cardiac arrhythmias within one year of study Day 1
• Subjects with congestive heart failure
• Subjects with uncontrolled Stage III hypertension
• Triglycerides >1000 mg/dL at Screening
• Known history of HIV or hepatitis C
• History of illicit drug or alcohol abuse with one year of study Day 1
• Have had 2 or more emergency room visits, doctor visits, or hospitalizations due to hypoglycemia within 6 months of study Day 1
• Use of any other investigational drug within 30 days of study Day 1
• Prior exposure to LX4211
• Use of any medication or herbal supplement for the purpose of weight loss
• Chronic use of any antidiabetic therapy other than metformin in the 3 months prior to study Day 1
• Use of corticosteroids within 2 weeks prior to study Day 1
• Major surgery within 6 months of study Day 1
• Subjects with any history of severe gastroparesis
• Inability or difficulty swallowing whole capsules or tablets
• Women who are pregnant or breast feeding

Where it is running

• Lexicon Investigational Site — Carmichael, California, United States
• Lexicon Investigational Site — Greenbrae, California, United States
• Lexicon Investigational Site — La Jolla, California, United States
• Lexicon Investigational Site — Northridge, California, United States
• Lexicon Investigational Site — Orange, California, United States
• Lexicon Investigational Site — Pismo Beach, California, United States
• Lexicon Investigational Site — Tarzana, California, United States
• Lexicon Investigational Site — Tustin, California, United States
• Lexicon Investigational Site — Denver, Colorado, United States
• Lexicon Investigational Site — Denver, Colorado, United States
• Lexicon Investigational Site — Newark, Delaware, United States
• Lexicon Investigational Site — Edgewater, Florida, United States
• Lexicon Investigational Site — Miami, Florida, United States
• Lexicon Investigational Site — Orlando, Florida, United States
• Lexicon Investigational Site — West Palm Beach, Florida, United States
• Lexicon Investigational Site — Winter Park, Florida, United States
• Lexicon Investigational Site — Blue Ridge, Georgia, United States
• Lexicon Investigational Site — Savannah, Georgia, United States
• Lexicon Investigational Site — Lafayette, Indiana, United States
• Lexicon Investigational Site — Madisonville, Kentucky, United States
• Lexicon Investigational Site — Baton Rouge, Louisiana, United States
• Lexicon Investigational Site — Brockton, Massachusetts, United States
• Lexicon Investigational Site — Waltham, Massachusetts, United States
• Lexicon Investigational Site — Traverse City, Michigan, United States
• Lexicon Investigational Site — Anaheim, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.